relapsing-remitting multiple sclerosis

E121346

Relapsing-remitting multiple sclerosis is the most common form of multiple sclerosis, characterized by clearly defined attacks of neurological symptoms followed by periods of partial or complete recovery.

All labels observed (1)

Label Occurrences
relapsing-remitting multiple sclerosis canonical 2

How this entity was disambiguated

Statements (51)

Predicate Object
instanceOf autoimmune disease subtype
clinical course subtype of multiple sclerosis
neurological disease subtype
affectsAnatomicalLocation brain
central nervous system
spinal cord
canProgressTo secondary progressive multiple sclerosis
characterizedBy clearly defined relapses of neurological dysfunction
episodes of new or worsening neurological symptoms
periods of partial or complete remission
commonSymptom ataxia
bladder dysfunction
cognitive impairment
fatigue
motor weakness
optic neuritis
sensory disturbances
diagnosedBy MRI evidence of demyelinating lesions disseminated in time and space
clinical history of relapses and remissions
exclusion of alternative diagnoses
epidemiology accounts for majority of multiple sclerosis cases at diagnosis
more prevalent in regions with higher latitude
hasAbbreviation RRMS
hasCoursePattern relapsing
remitting
hasPrognosis better early prognosis than progressive forms of multiple sclerosis
variable long-term disability accumulation
hasSexPredominance more common in females than males
hasUnderlyingMechanism immune-mediated demyelination in central nervous system
inflammatory lesions in brain and spinal cord
isMostCommonFormOf multiple sclerosis
mayShowOnMRI T2 hyperintense lesions in white matter
gadolinium-enhancing lesions during relapses
partOf multiple sclerosis disease spectrum
relapseDuration at least 24 hours
relapseSeparationInterval at least 30 days between attacks
relapseTreatment high-dose corticosteroids
remissionCharacteristic complete recovery of function in some patients
partial recovery of function
riskFactor genetic susceptibility
prior Epstein–Barr virus infection
smoking
vitamin D deficiency
treatedWith disease-modifying therapies
fingolimod
glatiramer acetate
interferon beta preparations
Tysabri
surface form: natalizumab

ocrelizumab
typicalOnsetAgeRange 20–40 years
early adulthood

How these facts were elicited

Referenced by (2)

Full triples — surface form annotated when it differs from this entity's canonical label.

Josiah Bartlet medicalCondition relapsing-remitting multiple sclerosis
Vumerity indicatedFor relapsing-remitting multiple sclerosis